Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Participants With Obesity or Overweight and Chronic Low Back Pain
NCT07035093Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- Sep 2027
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of retatrutide in obesity, chronic low back pain (CLBP), sponsored by Eli Lilly and Company. Started May 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesitychronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT07035093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035093.